{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-006042","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.566728+00:00","generated_at":"2026-05-17T14:08:55.974424+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aethlon Medical reports Q1 FY2026 operating loss of $1.8M; cancer trial advances to second cohort","bullets":["Operating loss narrowed to $1.8M from $2.6M YoY; cash balance $3.8M at June 30, 2025.","First cohort completed in Australian Hemopurifier cancer trial; DSMB approves second cohort with two treatments.","Amended protocol broadens eligibility to any anti-PD-1 regimen; preclinical data show 98.5% removal of platelet-derived EVs.","India oncology study dropped due to extended timeline; Long COVID research with UCSF presented at Keystone Symposium."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-006042","json":"https://secwatch.observer/filing/0001683168-25-006042.json","markdown":"https://secwatch.observer/filing/0001683168-25-006042.md","text":"https://secwatch.observer/filing/0001683168-25-006042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316825006042/0001683168-25-006042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316825006042/aemd_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:08:55.974424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}